Looks like ARCH Venture Partners is gearing up for its ninth fund, with aims to raise $400 million, according to a regulatory filing. The Chicago-based early stage venture firm has a deep history in tech and life sciences investments – with some notable recent plays like Illumina offshoot Grail, Harvard 3D printing spinout Voxel 8, and Doug Williams’ brainchild Codiak Biosciences.
The amount being raised in this newest fund is in line with ARCH’s previous funds: Its eighth, for instance, raised $410 million in 2014 and its seventh raised $400 million in 2007. MedCity News is waiting to hear back from the firm to learn about its plans for fund nine.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
ARCH Venture Partners maintains offices in Austin, Chicago, Seattle, San Francisco, and Dublin, Ireland. With its first eight funds, it has two $2 billion in assets under management and has invested in some 180 companies.
Some of its more notable portfolio companies include Bluebird Bio, Illumina and Receptos.
